Gibco™ Human TNF-RI (soluble) Recombinant Protein 

Description

Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute sTNF-RI in 5 mM Tris, pH 8.0, to a concentration of 0.1-1.0 mg/mL. Further dilutions should be made in aqueous buffers supplemented with carrier protein, such as 0.1-1.0% BSA. Storage: This lyophilized preparation is stable at 2°C to 8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2°C to 8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C. Avoid repeated freeze/thaw cycles.

TNFR1 (Tumor necrosis factor receptor 1) belongs to the tumor necrosis factor superfamily, and is one of the major TNF-alpha receptors. TNFR1 plays an important role in mediating, in cytokine mediated signaling, positive regulation of the NF-Kb pathway, positive regulation of angiogenesis, and negative regulation of gene expression. The extracellular domain of TNFR1 is also released into the circulatory system as soluble TNFR1 (sTNFR1). In humans, the TNFR1 gene is located on chromosome 12. Anti-apoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRADD and TRAF2 have been shown to interact with TNFR1, and thus play regulatory roles in the signal transduction mediated by the receptor. Germline mutations of the extracellular domains of TNFR1 were found to be associated with the autosomal dominant periodic fever syndrome, and the impaired receptor clearance is thought to be a mechanism of the disease.